Safety check: tracking babies born to moms on skin treatment
NCT ID NCT03992729
Summary
This study aims to understand the safety of the medication tildrakizumab during pregnancy. Researchers will follow 200 pregnant women who are taking the drug for approved skin conditions and compare their pregnancy and infant outcomes to similar women not taking the drug. The goal is to collect information on birth defects, miscarriages, and infant health up to one year of age.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANCY RELATED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Christina Chambers
RECRUITINGSan Diego, California, 92093, United States
Conditions
Explore the condition pages connected to this study.